Lumiliximab

From Self-sufficiency
Jump to: navigation, search
Lumiliximab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target CD23
Identifiers
ATC code none
Chemical data
Formula C2115H3252N556O673S16
Molar mass 47.75 kDa[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Lumiliximab is a monoclonal antibody that targets CD23. It acts as an immunomodulator[1] and, as of October 2009, it is being investigated in Phase I and II clinical trials for the treatment of chronic lymphocytic leukemia.[2][3] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]

References

  1. ↑ 1.0 1.1 International Nonproprietary Names for Pharmaceutical Substances (INN). World Health Organization.
  2. ↑ Byrd, J. C.; Kipps, T. J.; Flinn, I. W.; Castro, J.; Lin, T. S.; Wierda, W.; Heerema, N.; Woodworth, J.; Hughes, S. (2009). "Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia". Blood. 115 (3): 489. doi:10.1182/blood-2009-08-237727. PMC 2810983 Freely accessible. PMID 19843887.  edit
  3. ↑ ClinicalTrials.gov NCT00801060
Intracellular
(initiation)
Macrolides/
other IL-2 inhibitors
TNF-α inhibitor
Intracellular
(reception)
Extracellular
Serum target
(noncellular)
Cellular target
Unsorted
-cept (Fusion)
"-tuxi-" (tumor/cancer immunotherapy)
"-cixi-" (cardiovascular)
"-lixi-" (immune system)
"-mexi-" (melanoma)
"-baxi-" (bacterial)


40x30px This monoclonal antibody-related article is a stub. You can help ssf by expanding it.
40px This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it.
es:Lumiliximab
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Lumiliximab&oldid=23072"